BLCO Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Revenue Outlook: Bausch + Lomb Corp. (BLCO) announced its FY25 revenue outlook, expecting $4.95 billion to $5.05 billion, aligning with analyst estimates of $5.02 billion. This stability suggests consistent performance but may not drive significant price movement.
CEO's Transparency Advocacy: CEO Brent Saunders emphasized the need for pricing transparency in healthcare, drawing comparisons to Elon Musk's approach. While this reflects strong leadership, its direct impact on stock price is unclear.
Product Launch: The launch of the Arise lens fitting system highlights BLCO's commitment to innovation in orthokeratology. This could enhance market positioning but may not immediately affect next week's price.
Technical Analysis:
- RSI: BLCO's RSI is 35.76, indicating oversold conditions, suggesting potential for a bounce.
- MACD: The MACD is slightly negative (-0.38), showing mild bearish momentum.
- Fibonacci Levels: Key resistance at $16.04 and $16.30, with support at $15.22 and $14.96.
Price Prediction and Recommendation:
Given the oversold RSI and nearby support, BLCO may experience a slight rebound. However, resistance levels and limited catalysts suggest modest upside. The stock is expected to trade between $15.50 and $15.80 next week.
Recommendation: Buy at current levels with a target of $15.80, as the stock approaches oversold territory and shows pre-market buying interest.
BLCO Similar Chart Price Prediction
The price of BLCO is predicted to go up -9.79%, based on the high correlation periods with PLMR. The similarity of these two price pattern on the periods is 96.25%.
BLCO
PLMR
Down: -9.79%Similarity: 96.25%
BLCO Revenue Forecast
BLCO EPS Forecast
BLCO FAQs
What is BLCO revenue forecast for next quarter？
What is BLCO eps forecast for next quarter？
BLCO VS S&P500
As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company.
With an upcoming launch of multifocal and toric lenses in the Infuse line (daily silicone hydrogels), we expect Bausch to win over some new customers as well as to have its current Bausch lens wearers upgrade.
We expect patents and product superiority of Biotrue eye drops, Lumify, and PreserVision to secure Bausch as a leader in the over-the-counter eye care and supplements space.
BLCO Analyst's Forecast
Yi Chen
HC Wainwright & Co.
Strong Buy
2025-02-21
Price Target
$23 → $20
Upside
+26.18%
BofA lowered the firm's price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Underperform rating on the shares. 2025 guidance, particularly EBITDA, likely disappointed investors even though B+L signaled lower expectations in early January, notes the analyst. The firm continues to believe the stock upside is limited until investors get more visibility into Bausch + Lomb's separation from Bausch Health (BHC), the analyst added.
Yi Chen
HC Wainwright & Co.
Strong Buy
2024-12-12
Price Target
$23
Upside
+22.99%
Joanne Wuensch
Citigroup
Strong Buy → Hold
2024-12-11
Price Target
$24 → $22
Upside
+21.21%
